topotecan

Overview

Topotecan is a topoisomerase I inhibitor used in relapsed ovarian cancer, small-cell lung cancer, and pediatric solid tumors. In sarcoma it has been evaluated in functional drug screens as a single agent.

Evidence in the corpus

• Osteosarcoma PDTOs from the UCLA functional screen were significantly more sensitive to topotecan than the pan-sarcoma average (p=0.028). PMID:39305899
• LMS PDTOs were significantly less sensitive to topotecan than the pan-sarcoma average (p=0.031), consistent with prior negative clinical trial data in leiomyosarcoma. PMID:39305899
• Included in the CCLE pharmacogenomic screen across 947 cancer cell lines; sensitivity correlated with genomic features via elastic-net regression PMID:22460905
• Cross-resistance to topotecan observed in SCLC chemoresistant PDX models; SLFN11 re-expression via EZH2 inhibitor EPZ011989 re-sensitized cell lines to topotecan (Pearson r = 0.916 correlation between SLFN11 re-expression and sensitization); ectopic SLFN11 was sufficient to sensitize NCI-H82 and NCI-H446 PMID:28196596.

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• OS, LMS

Sources

• PMID:39305899 — Duminuco et al. 2024, UCLA PDTO sarcoma functional screen; osteosarcoma sensitivity (p=0.028) and leiomyosarcoma resistance (p=0.031).

This page was processed by entity-page-writer on 2026-05-01. - PMID:22460905

This page was processed by wiki-cli on 2026-05-06. - PMID:28196596

This page was processed by wiki-cli on 2026-05-14.